Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 704.24

+1.6%

Nov 17 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	3/16/2018 3:32:31 PM
	of 3559

Interesting read on Praluent v Repatha IP litigation: markmanadvisors.com I am not layman, and can't comprehend what is going on in court, but im my "lawman" view one can not (it has no logic) patent biologic "sweet spot" and corresponding ligands that bind to that "sweet spot" without describing interaction and what is ligand characteristic in that interaction (sub-ligand moiety, sub-structure). What is valid for small molecule should hold for biologic. I still believe that REGN has upper hand in this litigation, and that this time their lawyers will do BETTER JOB!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next